[Cell protection through PPAR nuclear receptor activation].
Apart from their effects on lipid and glucose metabolism, the nuclear receptors PPARs (peroxysome proliferator-activated receptors) could also be involved in cellular protection. Indeed, an increasing body of literature provides arguments in favour of a protective role of PPAR alpha (fenofibrate, gemfibrozil) and PPAR gamma (ciglitazone, pioglitazone, rosiglitazone, troglitazone) agonists, particularly in myocardial or cerebral ischaemia as well as in neurodegenerative diseases. Such cellular protection could be the result of the modulation, at a molecular level, of inflammation pathways, oxidative stress and apoptosis. If these experimental results are confirmed by appropriate clinical trials, pharmacological modulation of the nuclear receptor PPARs, as well as the development of highly selective and more effective PPAR agonists, could become an important challenge in the field of cellular protection.
Deplanque
Dominique
D
EA 1046, Laboratoire de Pharmacologie, Faculté de Médecine, Lille, France. d-deplanque@chru-lille.fr
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D002545:Brain Ischemia / Q000188:drug therapy / Q000503:physiopathology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000502:physiology*; D014157:Transcription Factors / Q000819:agonists / Q000502:physiology*
D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors